Last reviewed · How we verify
NKG2D CAR-NK
At a glance
| Generic name | NKG2D CAR-NK |
|---|---|
| Also known as | Natural killer group 2 member D (NKG2D) ligand-targeting chimeric antigen receptor (CAR) natural killer (NK) cells |
| Sponsor | Hangzhou Cheetah Cell Therapeutics Co., Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Hepatic Artery Transfusion of NKG2D CAR-NK Cells Followed by Intravenous Infusion of NKG2D CAR-T Cells to Treat Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments: a Phase I Exploratory Clinical Trial (PHASE1)
- Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC (PHASE1, PHASE2)
- NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS (PHASE1)
- A Trail of Second-line Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer (EARLY_PHASE1)
- Endoscopic Ultrasound (EUS) Intratumoral Injection of CAR-NK Cells in the Treatment of Advanced Pancreatic Cancer (EARLY_PHASE1)
- An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma (EARLY_PHASE1)
- NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer (PHASE1)
- NKG2D CAR-NK & Ovarian Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NKG2D CAR-NK CI brief — competitive landscape report
- NKG2D CAR-NK updates RSS · CI watch RSS
- Hangzhou Cheetah Cell Therapeutics Co., Ltd portfolio CI